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Enrique Lara-Pezzi1, Elke Dworatzek2 and Fernando Rodríguez-Pascual3*Abstract
The Workshop on Cardiovascular Extracellular Matrix in Health and Disease, International University of Andalusia,
Baeza, Spain, 6-8 October 2014 served to discuss the current knowledge on the mechanisms integral to extracellular
matrix homeostasis that are fundamental to understanding the pathological basis of several cardiovascular diseases,
including the development of cardiac fibrosis in response to cardiac hypertrophy and myocardial infarction, and the
extracellular matrix alterations contributing to aortic stenosis or aneurysms.
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Clearly distinguishable from the glycocalix, the membrane-
bound, carbohydrate-rich cell coat, the extracellular matrix
(ECM) constitutes the organic matter found between most
cells in plants and animals. Over recent years, our under-
standing of the functions of the ECM has evolved from the
traditional concept of static ‘glue’, holding cells into tissues,
to a more sophisticated view of a dynamic biomaterial that
provides strength and elasticity, as well as anchor points of
interactions with cell surface receptors, and availability of
growth factors. Proper formation and organization of the
ECM is essential for cell and tissue homeostasis. Matrix-
related diseases arise from defects in the properties of ECM
components, as in congenital diseases such as Marfan and
Ehlers-Danlos syndromes, and from an excess of ECM pro-
duction and deposition, generally termed as fibrosis. The
International University of Andalusia Workshop ‘Current
Trends in Biomedicine’ on Cardiovascular Extracellular
Matrix in Health and Disease, was organized by Harry C.
Dietz, Nadia Mercader and Paul R. Riley in Baeza, Spain,
from 6 to 8 October 2014 with almost 50 attendees includ-
ing basic as well as clinical scientists (Figure 1). The meet-
ing aimed to bring together top-level, highly experienced
investigators working on different aspects of cardiovascular
ECM pathophysiology and mechanisms of fibrosis initi-
ation, propagation, and regression in an attempt to shed* Correspondence: frodriguez@cbm.csic.es
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to progress into the development of new therapeutic
strategies.
Four main sessions covered the role of fibrosis in cardiac
remodeling, general mechanisms for tissue fibrosis, and
the contribution of matrix remodeling to aortic diseases.
A final session discussed novel therapeutics in cardio-
vascular diseases and tissue remodeling. The following
sections will give an overview of the scientific content of
the meeting.The cardiovascular extracellular matrix
In vertebrates, where the circulatory system consists of a
central pump (the heart) and a network of tubes (the
vasculature), through which the blood is continuously
circulated, the ECM plays an essential role in determin-
ing the mechanical properties of the vascular and cardiac
tissues. The main components of the cardiovascular
ECM responsible for its biomechanical behavior include
elastin and collagen. Considering the vascular scenarios
where the blood pressure is at highest, namely the heart
and the aorta, an exquisite combination of collagen and
elastin provides the aortic tissue with its properties of
strength and recoil, respectively. In the heart, cardio-
myocytes are embedded in a collagen network, which is
essential for contraction but is also implicated in the
tissue response to damage.ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Official poster announcement of the International University of Andalusia Workshop ‘Current Trends in Biomedicine’ on
Cardiovascular Extracellular Matrix in Health and Disease, Baeza, Spain, 6-8 October 2014. Image shows a cryoinjured zebrafish heart,
image courtesy of Juan Manuel González-Rosa.
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Extensive ECM remodeling occurs in the diseased heart.
Irrespective of whether cardiomyocyte loss occurs because
of an ischemic event, such as a myocardial infarction, or
as a response to pressure or volume overload or the result
of congenital cardiomyopathies, damage to the myocar-
dium results in severe alterations of the cardiac collagen
network. The molecular mechanisms governing these pro-
cesses and the therapeutic opportunities that arise from
their understanding are an active area of research.
Myofibroblasts constitute the main cellular effectors of
cardiac fibrosis, and the activation of transforming growth
factor-β (TGF-β) is likely the most important signaling
pathway contributing to myofibroblast differentiation.
Nikolaos G. Frangogiannis (Albert Einstein College of
Medicine, USA) described the effects of suppressing
Smad3 specifically in periostin-positive myofibroblasts.
Periostin is not expressed in healthy adult hearts, but is
markedly and selectively upregulated in activated injury-
site myofibroblasts. The group of Frangogiannis observed
accentuated cardiac remodeling associated with defective
scar contraction in myofibroblast-specific Smad3 knock-
out mice. Interestingly, Smad3 loss perturbs spatial align-
ment of infarct myofibroblasts, a typical response linked
to the deposition of long and highly aligned collagen fibers
in the infarct area. An important issue, still a matter of
intense debate, is the origin of myofibroblasts in the dam-
aged heart. Onur Kanisicak from the group of Jeffery D.
Molkentin (Cincinnati Children’s Hospital Medical Center,
USA) approached the study of myofibroblast ontogeny by
tracing fibroblasts in TCF21- and periostin-Cre mouse
lines. According to their results, TCF21 labels quiescent
fibroblasts within the adult heart. Upon myocardial
damage, these cells first give rise to proto-myofibroblasts
expressing both TCF21 and periostin, and finally to
periostin-positive myofibroblasts committed to cardiac
fibrosis and remodeling. Epicardial- and bone marrow-
derived cells have also been shown to contribute to acti-
vated myofibroblasts within the damaged heart. José
María Pérez-Pomares (University of Málaga, Spain) and
Adrián Ruiz-Villalba (Academical Medical Center, The
Netherlands) described the exquisite cell-cell interaction
between both cell types for patterned collagen deposition,
being epicardial-derived fibroblasts mostly responsible for
collagen expression. Inflammatory cells such as macro-
phages are also important players in the tissue response to
heart damage. Thomas Braun (Max-Planck-Institute for
Heart and Lung Research, Germany) showed the potential
of the macrophage cytokine oncostatin M to dedifferen-
tiate cardiomyocytes and thereby providing protective
effects during myocardial infarction.
In contrast to adult mammals, an impressive regenerative
capacity has been demonstrated in the hearts of zebrafish
and newts. These animals display a robust proliferativecompetence of cardiomyocytes in adult life, which provides
a source to form a new myocardium after injury. Nadia
Mercader (Centro Nacional de Investigaciones Cardio-
vasculares, Spain) described the potential of models of
cryoinjury-induced heart damage in zebrafish to elucidate
the processes underlying the regeneration capacity, with
particular interest in the origin of cells contributing to
scar formation and regression. Rebeca Richardson from
the group of Paul Martin (University of Bristol, United
Kingdom) emphasized also the remarkable competence
of embryos and adult teleosts for complete, scar-less
tissue regeneration, not only in heart but also in skin, and
the important role of the inflammatory cell response to
complete this process.
Research on specific ECM or ECM-associated proteins is
revealing also important clues on tissue remodeling during
heart damage. Nathalie Pizzinat (Institute of Cardiovascular
and Metabolic Diseases, France) discussed the role of
the ECM glycoprotein tenascin C in pressure overload-
induced cardiac dysfunction. Tenascin C deficient mice
show reduced accumulation of inflammatory cytokines and
chemokines as well as diminished leukocyte recruitment
upon heart damage, compared to wild type animals. Add-
itionally, Fernando Rodriguez-Pascual (Centro de Biología
Molecular, Spain) discussed the contribution of matrix
crosslinking lysyl oxidases to collagen scar formation
and cardiac dysfunction upon myocardial remodeling. As
shown by his group, inhibition of lysyl oxidase enzymatic
activity impaired collagen cross-linking, an effect associ-
ated with improved cardiac function.
An interesting presentation from Elke Dworatzek (Uni-
versitaetsmedizin Berlin, Germany) showed dimorphic
collagen expression in male versus female pressure
overload-induced hearts, an observation probably relying
on differential estrogen-mediated signaling in cardiac
fibroblasts.
Finally, the development of cardiac fibrosis is also
regulated by the actions of miRNAs. This was highlighted
by Esther Creemers (Academic Medical Center, The
Netherlands), who described the capacity of miRNA-15
family to regulate TGF-β signaling and thereby to control
cardiac fibrosis.
Fibrosis in other tissues helps to decipher cardiac fibrosis
While undoubtedly showing tissue-specific features, cardiac
fibrosis is also governed by general mechanisms of tissue
fibrosis. An example of a molecular pathway contributing
to fibrosis in a global way is the transient receptor potential
canonical member 6 (TRPC6), an integral membrane cal-
cium channel described to be essential for cardiac, dermal,
and embryonic fibroblasts to transdifferentiate into fibrosis-
competent myofibroblasts, as shown by Molkentin. Pura
Muñoz-Canoves (Pompeu Fabra University and ICREA,
Spain) has studied the issue of the myofibroblast origin in
Lara-Pezzi et al. Fibrogenesis & Tissue Repair  (2015) 8:2 Page 4 of 5the context of muscular dystrophies. Distinct genetically
engineered mice enabled her group to trace and map
the origin of these cells. They proposed that, in addition
to resident fibroblasts, myoblast cells and other resident
and infiltrating cell types within skeletal muscle transit
into myofibroblasts during muscular dystrophy. To this
respect, Raghu Kalluri (University of Texas, USA) revised
the concept of cellular plasticity in the pathogenesis of
fibrosis, with particular emphasis on the contribution of
the endothelial-to-mesenchymal transition to this process.
Jelena Mann (University of Newcastle, United Kingdom)
discussed the influence of epigenetics to regulate the
progression of chronic liver fibrosis. She showed how
an epigenetically regulated fibrotic signature can be
transmitted from one generation to its offspring, and
from one organ to another within an organism.
Matrix remodeling in aortic diseases
In the arterial wall, elastin and collagen deposited mainly
(but not exclusively) by vascular smooth muscle cells
provide the tissue with specific biomechanical features.
Elastin organizes into a 3D-interconnecting lamellar net-
work designed to transfer the tremendous surge of pres-
sure as blood is ejected from the heart throughout the
vessel wall. On the other hand, bundles of collagen
between the lamellar layers progressively restrict aortic
distension at high pressures, contributing to the non-
linear nature of vascular elasticity, which is essential for
preventing distension and further damage to the vessel
with increased pressure. Alterations in ECM homeostasis
have been invoked to be the causative factor of a number
of aortopathies, including the formation of aortic aneu-
rysms or the development of aortic stiffness.
A paradigm disease in aortic pathology is Marfan syn-
drome (MFS), a hereditary connective tissue disorder
caused by mutations in the fibrillin-1 gene. Harry C. Dietz
(Johns Hopkins University, USA) discussed the funda-
mental role of the overactivation of TGF-β signaling in
the initiation and progression of the aneurysmal disease in
MFS, and the potential of the angiotensin receptor
blocker, losartan to ameliorate the aortic pathology. In
the search for gene modifiers, he introduced MAS1, an
antagonist of angiotensin signaling, and mitogen-activated
protein kinase kinase kinase 4 (MAP3K4), a central regu-
lator of MAPK pathway, as potential modifying loci for
MFS severity. Several investigations including those from
the group of Dietz situate TGF-β signaling downstream of
angiotensin activation along a pathway leading to aortic
dilatation in MFS. Nevertheless, refinements of the mouse
models by Jason R. Cook from the group of Francesco
Ramirez (Icahn School of Medicine at Mount Sinai, USA)
showed that both pathways could differentially contribute
to the initiation and progression of the aortic dilatation,
with mechanical stress playing a fundamental role in theactivation of angiotensin type 1 receptor in a ligand inde-
pendent manner. Additionally, Gustavo Egea (University
of Barcelona, Spain) described the TGF-β-dependent
phenotypic modulation of vascular smooth muscle cells in
MFS patients and mice. Furthermore, Rodriguez-Pascual
showed experimental results indicating a protective role
for matrix crosslinking lysyl oxidases in the formation of
aortic dilatation in MFS mouse models.
MFS and related disorders including Loeys-Dietz or
aneurysm-osteoarthritis syndromes account for less than
5% of known thoracic aortic aneurysms. Genetic abnormal-
ities explain about 20% of the remaining 95% of patients,
and several studies have identified mutations in proteins
within the ECM and the contractile machinery associated
with thoracic aortic aneurysms. However, many gene
mutations remain to be discovered. Juan Miguel Redondo
(Centro Nacional de Investigaciones Cardiovasculares,
Spain) showed experimental results indicating an import-
ant role for the peptidase of the ADAMTS (a disintegrin
and metalloproteinase with thrombospondin motif) fam-
ily, ADAMTS1 in the molecular events contributing to
the formation of aortic aneurysms, suggesting that muta-
tions within this gene may be involved in human aortic
pathology.
Mechanical forces dominate the performance of the
vessel wall, especially in the large, elastic arteries. Jessica
Wagenseil (Washington University, USA) emphasized the
importance of this concept by showing experiments in
elastin- and fibulin-4 null mice. According to her results,
the development of aortic stenosis or aneurysms in these
mouse models may be determined by smooth muscle cells
from distinct embryonic origins that respond differently to
mechanical forces.
Finally, Rick Assoain (University of Pennsylvania, USA)
described the importance of the matrix metalloproteinase
(MMP) 12 in the development of aortic stiffness in cardio-
vascular diseases and during aging.
Novel therapeutics in cardiovascular diseases and tissue
remodeling
The ultimate aim of the investigation on ECM contribution
to cardiovascular diseases is the development of novel
therapeutic strategies. Different promising approaches have
been presented during the workshop. Enrique Lara-Pezzi
(Centro Nacional de Investigaciones Cardiovasculares,
Spain) explained the capacity of the naturally occurring
splicing variant of the calcineurin catalytic subunit
(CnAβ1), to ameliorate cardiac dysfunction in mouse
models of myocardial infarction and pressure overload-
induced hypertrophy, indicating CnAβ1 as an interesting
candidate for gene therapy in the heart. A systematic ap-
proach to identify small molecules displaying regenerative
capacity in in vitro models of heart damage was presented
by Paul R. Riley (University of Oxford, United Kingdom).
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Japan) revised the iterative process that led to the identifi-
cation of the transcription factor cocktail reprogramming
fibroblasts into cardiomyocytes as an attempt to develop
therapeutic strategies for heart repair and regeneration.
Concluding remarks
A highly interactive program of 3 days of duration, which
included full communications, short talks and poster
presentations, encouraged an interesting exchange of
ideas among scientists working on different diseases and
experimental models related to cardiovascular ECM patho-
physiology. The meeting unveiled the intense efforts that
are being carried out to decipher the molecular players and
cell types responsible for the development of cardiac and
vascular fibrosis. Improving our understanding of these
mechanisms will undoubtedly contribute to the develop-
ment of new therapeutic strategies to tackle fibrosis in
cardiovascular diseases and other related conditions.
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